Non-ionic surfactant nano-emulsions have extensive anti-microbial activity and are biocompatible with skin and mucous membranes at effective concentrations. Two nano-emulsion formulations (8N8 and 20N10) made from soybean oil, tributyl phosphate and Triton X-100, were tested for their ability to prevent murine influenza virus pneumonia in vivo. In the initial study, CD-1 mice were administered various dilutions of the nano-emulsions intranasally, and safe dosages and concentrations were determined. Non-toxic concentrations of the nano-emulsions were then mixed with influenza virus and applied to the nares of mice. Animals receiving mixtures of two different emulsions (8N8 or 20N10) and a LD 50 of virus survived the challenge without evidence of viral infection. To determine if the nanoemulsions could prevent influenza virus infec-Introduction ©2000 International Medical Press 0956-3202/00/$17.00canine kidney (MDCK) cells at concentrations as low as 1.0% (Myc et al., 1999) . Kinetic studies using a plaque reduction assay have also demonstrated that nano-emulsions completely inactivate influenza virus (4.23 log 10 reduction) at a concentration of 1.0% within 30 min. On the basis of this information, the present studies were designed to evaluate the toxicity of two non-phospholipid nano-emulsion formulations on murine nasal epithelium and pulmonary tissue. Once non-toxic concentrations were identified, the ability of these compounds to prevent influenza A virus infection when applied as prophylaxis was assessed in a murine influenza pneumonitis model previously developed for the testing of antiviral agents (Huang et al., 1991; Karaivanova & Spiro, 1998; Sidwell, 1999; Wyde et al. 1977) .
Materials and Methods: Virology
H Maassab (School of Public Health, University of Michigan, Ann Arbor, Mich., USA) graciously provided influenza virus strain A/AA/6/60 (H2N2). This virus was passaged in mice and documented to cause significant mortality. The virus was propagated in chicken embryos using standard methods (Barrett & Inglis, 1985) . Infectious allantoic fluid was aliquoted into samples containing ~10 7 p.f.u./ml, and stored at -80°C until use.
Materials and Methods: Chemistry
Based on previous in vitro studies of antiviral activity (Myc et al., 1999) , two formulations of nano-emulsion were prepared. An oil phase of tri-n-butyl phosphate, soybean oil and Triton X-100 was blended and heated at 86°C for 1 h, then emulsified in water using a reciprocating syringe pump or commercial emulsifier (Silverson Machines, East Longmeadow, Mass., USA). One nanoemulsion formulation (8N8) contained 8.0% Triton X-100 and 8.0% tri-n-butyl phosphate, whereas the second (20N10) was 20.0% Triton X-100 and 10.0% tri-n-butyl phosphate. Nano-emulsion particle sizes were measured using a Coulter LS 130 laser-sizing instrument. The size of nano-emulsions ranged from 223-228 nm and 95% of particles had a diameter less than 226 nm. The 8N8 emulsion had a hydration ratio of 1:4 and pH 7.68, whereas the 20N10 emulsion had a hydration ratio of 41:9 and pH 7.69. All subsequent dilutions of the emulsions were made in PBS.
Murine respiratory toxicity assay Four-to 5-week-old specific-pathogen-free CD-1 mice (Charles River, Portage, Mich., USA) of either sex were randomly assigned into groups of three and housed accordingly with free access to food and water. The animals were anaesthetized with metofane in a bell jar and inoculated with 50 µl total (25 µl/nare) test material (PBS, 8N8 at concentrations of 10.0, 1.0 or 0.1% or 20N10 at a concentration of 1.0%). The mice were observed for abnormalities during recovery, and checked at least daily after inoculation over a period of 5 days. On day 5, all surviving mice were humanely euthanized with metofane and tissues were harvested. The lungs, trachea and nasal turbinates were inflated and fixed in 10.0% buffered formalin for histopathology. Nasal turbinates were demineralized for 48 h in Cal-Ex solution (Fischer Scientific, N.J., USA) before paraffin embedding.
In vivo virus inhibition study Two models of predictable and consistent murine viral pneumonia were established. Once the models were verified, CD-1 mice were divided into groups of at least five animals to perform the studies on. In the first model, anaesthetized animals were administered 50 µl (25 µl/nare) intranasally of either PBS, 10 5 p.f.u./ml influenza A virus in PBS or 10 5 p.f.u./ml virus mixed with either 1.0, 0.2 or 0.1% 8N8 or 1.0, 0.2, 0.1 or 0.02% 20N10. The development of viral pneumonia was monitored for a 5 day period. In the second model, mice were anaesthetized and pretreated intranasally with 25 µl (12.5 µl/nare) of test material (8N8 at 1.0% or 20N10 at 1.0 or 0.2%). Control mice received PBS only. After 90 minutes, fully recovered animals were secured within a nebulization chamber and exposed to nebulized influenza virus at a concentration of 5×10 5 p.f.u./ml for 5 min. The mouthpiece of a PARI LC Jet+ nebulizer (PARI Respiratory, Richmond, Va., USA) (delivering 0.32 ml/min with a particle size from 0.5-5 µm) modified with a short section of clear tubing was inserted into one end of the nebulization chamber. A Proneb compressor was used to deliver the aerosol into the sealed chamber and an exhaust tube was run through a bleach bath. Owing to the confined space and the restricted movement of the animals within the tubes, the 5 minute exposure time was chosen to significantly reduce stress during the experimental procedure. Upon completion of the exposure period, mice were removed from the chamber and monitored daily for signs of illness over a period of 14 days. Animals in the first model developed appreciable clinical signs of infection within 3 days. In the second model, clinical signs of morbidity emerged 6-7 days after a 5 minute exposure to aerosolized influenza virus [5×10 5 p.f.u./ml; mortality ratio (n=4/5) 80.0%].
In both disease models, rectal core body temperatures were recorded with a Model BAT-12 digital thermometer fitted with a RET-3 type T mouse rectal probe (Physitemp, Clifton, N.J., USA) (Wong et al., 1997) . Temperature measurement time-points were carefully adhered to because of the natural diurnal fluctuation of body temperature in mice (Clement et al., 1989) . Clinical signs of illness were graded on a scale of 0-3, where 0 indicated no significant clinical abnormality; 1 indicated mild symptoms including piloerection, hunched back and loss of movement; 2 indicated cyanosis, dyspnea, circulatory compromise, tachypnea and a rectal temperature <33°C; and 3 indicated death of the animal. Mice with core body temperatures falling below 33°C were judged to be terminally moribund and humanely euthanized. Gross pathology of the lungs was quantified using a standard technique (Scott & Sydiskis, 1976) with minor modification. Focal lung lesions without consolidation were given a score of 0, whereas a score of 1 represented ≤25% consolidation, a score of 2 ≤50% consolidation and a score of 4 signified 100% pulmonary consolidation coinciding with death of the animal. The right lung lobes were aseptically removed, weighed and frozen at -80°C for determination of virus presence via plaque assay.
Identification of virus within the lung tissue
The presence of influenza A virus in lung tissue was detected by plaque assay, as described elsewhere (Myc et al., 1999) . The right lung was thawed at room temperature and homogenized in a 7 ml sterile tissue grinder (Wheaton Science Products, Millville, N.J., USA) in serum-free MEM. This contained 0.1 mM MEM nonessential amino acid solution, 2 mM L-glutamine, 1.0 mM MEM sodium pyruvate, 100 U/ml penicillin 100 µg/ml streptomycin (GibcoBRL) with 3.0 µg/ml TPCK-treated trypsin (TPCK) (Worthington Biochemical Corporation, Lakewood, N.J., USA) to make a 10.0% (w/v) solution. Following homogenization, the sample was centrifuged at 2000-3000 r.p.m. for 10 min. The supernatant was serially diluted and plated on MDCK cells for plaque assay titration and viral presence was recorded.
Statistics and data interpretation
The means, standard deviation, standard error, and χ 2 analysis with Yate's correction were calculated. To compare the control group to the study groups, Cox regression (Cox, 1972) was used. Difference between the study groups and the control group was tested using the log-likelihood ratio test.
Results
Toxicity When a 10.0% concentration of either the 8N8 or 20N10 nano-emulsion formulations was applied to mice nares, acute dyspnea, serosanguinous nasal discharge and cyanosis occurred in all animals and 4 of 5 mice died before anaesthetic recovery. Histopathology demonstrated marked nasal epithelial erosion and patchy necrosis of the bronchial mucosa with a focal pneumonitis. No residual lipid was observed in the lung, but the pulmonary macrophages appeared foamy and contained several clear vacuolated areas of presumed lipid phagocytosis. At a concentration of 1.0%, both the 8N8 and 20N10 formulations were well tolerated after direct intranasal instillation in mice. Mice recovering from anesthesia appeared healthy the following day and survived the 5 day observation period without problems. Upon euthanization at day 5, no clinical, gross or histopathologic changes were evident in mice receiving the 1.0% nano-emulsion pretreatment. There was also Figure 2 . †An acute death during nano-emulsion-virus mixture instillation owing to obstruction of airway.
no histopathologic evidence of injury to the nasal cavity or lungs in these animals.
Concurrent mixture of influenza A and nanoemulsion applied in vivo
Based on toxicity data, nano-emulsion concentrations of 1.0% or lower were studied further. Animals were administered influenza virus mixed with either 8N8 (at a concentration of 1.0, 0.2 or 0.1%) or 20N10 (at a concentration of 1.0, 0.2, 0.1 or 0.02%). As shown in Table  1 , significant mortality resulting from viral pneumonitis was seen in mice that received 8N8 at concentrations of 0.1% and 0.2% and mice that received 20N10 at concentrations of 0.1% and 0.02%. The lungs of infected mice were red, swollen and failed to collapse when the thoracic cavity was entered. Histopathology demonstrated a marked bronchointerstitial pneumonia and consolidation with a mixed mononuclear and neutrophilic inflammatory cell infiltrate (Figure 1b , c and f ). There were no deaths related to the development of pneumonitis in groups of mice receiving influenza virus mixed with 1.0% 8N8, 1.0% 20N10 or 0.2% 20N10 within the 5 day observation period (Figure 1a, d and e). This survival was dose-dependent as declining concentrations of nano-emulsion mixed with virus did not prevent pneumonitis or death (Figure 2 ).
Nano-emulsion prophylaxis of murine pneumonitis caused by inhalation of influenza virions Pretreatment of mouse nares with nano-emulsion followed by exposure to aerosolized influenza virus was performed to determine the ability of these compounds to protect mice against infection from inhaled virus particles. As the survival curve in Figure 3 shows, both the 8N8 (1.0%) and 20N10 (1.0 and 0.2%) nano-emulsions administered intranasally 90 min before exposure were significant prophylactic barriers to influenza infection. Cox regression model analysis revealed that there was no significant difference in survival between the three emulsion pretreatment groups. The difference between study groups compared to the control group was significant (P<0.005). Control mice, mock pretreated with an intranasal application of PBS, remained unprotected from a 5 min exposure to nebulized influenza A virus at a concentration of 5×10 5 p.f.u./ml. This concentration killed 81.25% (n=13/16) of control mice. In contrast, only 31.25% (n=5/16) of mice pretreated with 1.0% concentration of 20N10 died, whereas 37.5% (n= 6/16) of mice treated with a 0.2% concentration died (Table 2) . 8N8 also showed significant ability to protect mice from influenza infection. Only 26% (n=4/15, 1 mouse did not recover from anesthesia) of mice died when pretreated with 8N8 at a concentration of 1.0% (Table 2 ). The core body temperature in mice pretreated with either nanoemulsion did not drop below 33°C, however, this was commonly observed in the control group mice ( Figure  4 ). Surviving mice pretreated with nano-emulsion were free of influenza virions on day 14. In contrast, in either control mice or pretreated mice that died from pneumonitis, influenza virus was present in the lungs. The Cox regression model analysis revealed that there was no significant difference in survival between the three study groups. The overall difference between study groups compared to control group was significant (P<0.005). Individual animals with core body temperatures <33.0°C were humanly euthanized. lungs of control mice pretreated with PBS also show degradation and necrosis of alveolar epithelia and neutrophilic inflammatory cell infiltrate indicative of pneumonitis (Figure 5a ). In contrast, the lungs of emulsion pretreated mice surviving the 14 day observation period show only minimal inflammation with intact alveolar epithelia and an absence of obvious degradation and necrosis (Figure 5b, c, d ).
Discussion
Nano-emulsions offer a unique approach to the treatment of microbial pathogens. In contrast to liposomeencapsulated antimicrobials, which have been used for topical therapy (Reimer et al., 1997) , nano-emulsions do not serve as a vehicle for the delivery of an antimicrobial compound. It is the physical structure of the nanoemulsion itself that is the active agent. These compounds contain surfactants that specifically disrupt pathogenic microorganisms through membrane fusion and lysis of the targeted organism. In addition, emulsifying the detergent in oil significantly reduces toxicity to human and animal skin, mucous membranes and gastrointestinal tissues at antimicrobial concentrations. Nano-emulsions have the added advantages of being chemically stable, resistant to heat and adaptable for varying clinical and environmental applications. Because the compounds are predominately non-phospholipid-based, rapid oxidization of the lipid does not occur. The formulations are also relatively inexpensive to produce on an industrial scale (Azmin et al., 1985; Baille et al., 1986; Rogerson et al., 1988) . Previous preliminary studies documented that a 30 min incubation period of 8N8 at a concentration of 1.0% with influenza virus and several other enveloped viruses yielded greater than a 4 log 10 reduction in viral particles in vitro. This suggested that these nano-emulsions could be used to inhibit infection caused by pathogenic enveloped viruses and provided the impetus for testing as prophylactic barriers to enveloped virus infection in vivo. Intranasal application of these compounds and subsequent exposure to airborne influenza virions confirmed and expanded our in vitro findings. A significant proportion of mice pretreated with either of the nano-emulsion formulations survived exposure to a lethal dose of aerosolized influenza virus. The protection provided by the compounds lasted at least 90 min post-treatment, indicating that nano-emulsions sustained the ability to inhibit viral infection in vivo. These findings suggest the nano-emulsion may form a protective layer on the upper respiratory tract epithelia that prevents viral adhesion and simultaneously destroys free virus. The concept of a protective layer formed by the nano-emulsion is supported by both the lack of observable clinical signs indicative of influenza infection and the absence of inflammation in histopathological analysis of airway tissue from animals pretreated with nano-emulsion. Thus, the nanoemulsion appears to either prevent or attenuate the viral The issue of prevention versus attenuation is clarified in the body temperature curves of mice exposed to virus in the model two (nebulization chamber) studies. A consistent pattern seen in the temperature curves of these mice shows a decrease in core body temperature at 2 days post-exposure. This pattern was observed in all mice placed inside the nebulization chamber regardless of virus exposure. This early loss of temperature appeared to occur because of stress connected with experimental procedure and mice regained normal core temperatures by day 4 or 5. However, a distinct pattern was observed in infected mice at 6 to 7 days post-exposure. This latter temperature loss appeared to be the result of viral infection because the loss of temperature coincided with the emergence of clinical signs indicative of influenza infection. Most control mice were unable to recover and exhibited a continued decline in core body temperatures until death or euthanization occurred. Pretreated mice exhibited a similar decrease in core body temperature, but the mean temperature never reached 33°C and clinical signs were minimal. Temperature curves of pretreated mice uniformly returned to normal levels by the completion of the observation period at day 14. Overall, the decrease in body temperatures correlated well with other clinical signs of progressive viral infection in mice. Thus, it appeared that the pretreated mice had attenuated viral infections rather than absolute protection against infection. This is not surprising given the animals were only pretreated on one occasion and the emulsion probably dissipated before the virus was completely destroyed. Ongoing administration of the emulsion both before and after exposure may totally prevent infection by continuing to disrupt virus, and this type of protocol needs to be examined. Unfortunately, because of the need to anaesthetize the animals this is impossible to accomplish in mice.
The therapeutic index observed in these studies for the nano-emulsions is relatively narrow. Initial toxicity testing of the nano-emulsion formulations by installation of the compound to the nasal cavities of mice indicated that a 1.0% concentration of each nano-emulsion was well tolerated in experimental animals. However, to prevent viral pneumonitis, 8N8 requires a concentration of 1.0%, which is only 10 times lower than the concentration that causes mammalian toxicity. In contrast, the 20N10 formulation, which demonstrated a similar toxicity to 8N8, effectively inhibited influenza virus at concentrations down to 0.1%, yielding a broader therapeutic index (50-100 fold). This suggests that altering the mix of the components can develop improved formulations of the nano-emulsions with increased safety. It is also significant to note that current studies may overstate the toxicity of nano-emulsions. This is mainly because much of the nano-emulsion directly entered the lungs of anaesthetized animals. The immediate effect of aspirated oil on the lung is local haemorrhage and oedema from the obstruction of alveoli (Ikeda, 1935) . This phenomenon may explain most of the acute respiratory compromise and death observed in mice after receiving the nano-emulsion at concentrations of 10.0%. Lipid introduced into the lung in humans causes pneumonia and severe respiratory compromise, requiring aggressive and prolonged treatment. The type of oil and the amount of free fatty acid both determine the specific reaction to aspirated lipid (Annobil et al, 1997) . The unique composition of the nano-emulsion may explain the absence of lipid pneumonia in these mice, despite spillage of the material into the airways. The nano-emulsions employ soybean oil, which has a lower potential for causing lipoid pneumonia and pulmonary fibrosis than other oils which are known to cause severe pulmonary inflammation (mineral oil, animal-derived oils and those vegetable oils high in free fatty acids) (Ikeda, 1935; Pinkerton, 1927 Pinkerton, , 1928 . In these studies, no residual compound was observed in the lung 5 days post-inoculation, although macrophages appeared to be vacuolated and may have contained the phagocytized lipid. This information suggests that an intranasal application of nano-emulsion at concentrations lower than 1.0% should have safety comparable to other respiratory therapeutics (Annobil et al., 1997; Ikeda, 1935; Pinkerton, 1927) .
The application of these results to the prevention of natural influenza virus infections in humans is not clear. The murine model of pneumonitis is well accepted for testing antiviral agents, however there may be differences between these models and natural infection in humans. In mice, influenza infection has been reported to initially develop in the alveoli and spread to the upper respiratory tract (Hers et al., 1962) . In contrast, the infection in humans starts in the lower respiratory tract and descends to the lung parenchyma (Webster, 1994) . Application of nano-emulsions to mice under general anaesthesia allowed the compounds to reach the lungs because of a loss of mucociliary clearance and epiglottal function. It is presumed that nano-emulsion pretreatment resulted in local inactivation of influenza virus in these mice and with administration under anaesthesia this could have occurred in either the upper or lower airway. Thus, the capability of these nano-emulsions to prevent a natural influenza infection when applied only to the upper airway mucosa in humans cannot be determined using this model. It is interesting to postulate that only the upper airway needs to be treated in humans because it might prevent contamination at the initial site of influenza virus replication in the lower airway. However, confirmation of this will require clinical studies of naturally acquired respiratory virus infections in humans or primates.
In conclusion, initial in vivo studies with surfactant nano-emulsions suggest that these compounds offer a novel approach to preventing respiratory influenza infections. Further formulation evolution and the testing of efficacy in a clinical model of exposure that mimics human disease are warranted.
